Bitcoin price today: steady near $92k after sharp losses; Fed caution weighs
Investing.com -- Novartis (SIX:NOVN) projects sales will grow 5-6% annually through 2030, the Basel-based pharmaceutical company said on Wednesday, backed by eight products with peak sales potential of $3-10 billion each.
The Swiss drugmaker rolled forward its mid-term sales guidance to show a compound annual growth rate of 5-6% in constant currencies for 2025-2030, following an upgrade of its 2024-2029 guidance to 6% in constant currencies.
Novartis raised peak sales estimates for two products. Kisqali, a breast cancer treatment, increased to $10 billion from $8 billion. Scemblix, a leukemia medication, rose to $4 billion from $3 billion.
The company now has eight de-risked, in-market products with peak sales potential of $3-10 billion: Kisqali, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, Fabhalta and Rhapsido. The company said most carry issued U.S. patent protection throughout the 2030s.
"As a pure-play medicines company, Novartis has delivered a strong track record of sales growth with core margin expansion," CEO Vas Narasimhan said in a statement. "Looking ahead, we expect to sustain that momentum over the next five years, driven by assets we already have in hand as well as upcoming launches with multi-billion-dollar sales potential."
The drugmaker delivered a core operating income margin of 41.2% in the first nine months of 2025, reaching the level two years ahead of plan.
The company said it expects to return to above 40% margins by 2029, after absorbing 1-2 percentage points of dilution from the planned acquisition of Avidity Biosciences.
Novartis expects over 15 potentially submission-enabling readouts over the next two years. The company’s pipeline includes over 30 potential high-value medicines, with 10 licensed or acquired in the past two years. Narasimhan said Novartis has executed more than 30 strategic deals over the past two years.
The Avidity acquisition is expected to close in the first half of 2026, subject to completion of the separation of SpinCo from Avidity and other customary closing conditions.
Novartis announced the agreement to acquire the U.S.-based biotech company on Oct. 26. The pharmaceutical company’s pipeline spans four core therapeutic areas and advanced technology platforms. Novartis said its medicines reach nearly 300 million people worldwide.